Expertise in
14
conditions

Dr. Paul D. Richards

Salem, VA
Expertise in
14
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Expertise in
14
conditions
OverviewInsuranceLocationsClinical Research

Overview

Paul Richards is a Hematologist Oncology specialist and an Oncologist in Salem, Virginia. Dr. Richards is highly rated in 14 conditions, according to our data. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Richards is currently accepting new patients.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana
  •  Piedmont

Locations

1900 Electric Rd, Salem, VA 24153
540-774-8660

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: tucatinib, trastuzumab deruxtecan
Study Phase: Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

47 Total Publications

The gastrointestinal tract is a major source of the acute metformin-stimulated rise in GDF15.
The gastrointestinal tract is a major source of the acute metformin-stimulated rise in GDF15.
Journal: Scientific reports
Published: November 23, 2023
Similar Doctors
Expertise in
34
conditions
Dr. Jerome H. Goldschmidt
Hematology Oncology | Hematology | Oncology
Expertise in
34
conditions
Dr. Jerome H. Goldschmidt
Hematology Oncology | Hematology | Oncology

Oncology And Hematology Associates Of Southwest Virginia Inc

2013 Jefferson St Sw, 
Roanoke, VA 
 (4.9 mi)
540-982-0237
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jerome Goldschmidt is a Hematologist Oncology specialist and a Hematologist in Roanoke, Virginia. Dr. Goldschmidt is highly rated in 34 conditions, according to our data. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Goldschmidt is currently accepting new patients.

Expertise in
41
conditions
Dr. Vandana R. Karri
Hematology Oncology | Hematology | Oncology
Expertise in
41
conditions
Dr. Vandana R. Karri
Hematology Oncology | Hematology | Oncology

Lewis Gale Physicians LLC

1802 Braeburn Dr, 
Salem, VA 
 (0.1 mi)
540-772-3400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vandana Karri is a Hematologist Oncology specialist and a Hematologist in Salem, Virginia. Dr. Karri is highly rated in 41 conditions, according to our data. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Lung Cancer. Dr. Karri is currently accepting new patients.

Expertise in
37
conditions
Dr. Suzan R. Merten
Hematology Oncology | Oncology | Hematology
Expertise in
37
conditions
Dr. Suzan R. Merten
Hematology Oncology | Oncology | Hematology

Oncology And Hematology Associates Of Southwest Virginia Inc

2013 Jefferson St Sw, Fl 2, 
Roanoke, VA 
 (4.9 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzan Merten is a Hematologist Oncology specialist and an Oncologist in Roanoke, Virginia. Dr. Merten is highly rated in 37 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Breast Cancer, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Merten is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile